(HealthDay News) – For surgically menopausal women, testosterone administration correlates with improvements in several domains of sexual function, with evidence of a dose-dependent effect, according to a study presented at the annual meeting of The Endocrine Society, held from June 15–18 in San Francisco.
Grace Huang, MD, from the Boston University Medical Center, and colleagues examined the dose-dependent effects of graded doses of testosterone on sexual function in a cohort of 71 surgically menopausal women. Participants (mean age, 53 years) received a standardized transdermal estradiol regimen during a 12-week run-in period, and were then randomized to weekly intramuscular injections of testosterone enanthate (3, 6.25, 12.5, or 25mg) or placebo for 24 weeks.
The researchers found that there was a significant correlation between increases in free testosterone concentrations and changes in composite Brief Index of Sexual Functioning for Women scores, sexual thoughts-desire, arousal, and frequency of sexual activity. For women assigned to the 25-mg dose group, but not those in lower dose groups, the changes in sexual thoughts-desires and frequency of sexual activity were significantly greater than in women assigned to placebo. In the 25-mg dose group, sexual activity increased by 2.7 encounters per week, and changes correlated significantly with increases in the concentration of free testosterone. Compared with placebo, in the 12.5-mg and 25-mg dose groups, there were significant increases in the Psychological General Well-Being Index composite and vitality scores.
“This study provides novel information about the range of testosterone doses associated with potential beneficial effects on sexual function in women,” Huang said in a statement.